home / stock / gwii / gwii quote
Last: | $10.11 |
---|---|
Change Percent: | 0.0% |
Open: | $10.11 |
Close: | $10.11 |
High: | $10.11 |
Low: | $10.11 |
Volume: | 5,303 |
Last Trade Date Time: | 03/07/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$10.11 | $10.11 | $10.11 | $10.11 | $10.11 | 5,303 | 03-07-2023 |
$10.06 | $0 | $10.06 | $0 | $0 | 80 | 03-06-2023 |
$10.06 | $10.06 | $10.06 | $10.06 | $10.06 | 112 | 03-03-2023 |
$10.08 | $10.08 | $10.08 | $10.1 | $10.08 | 2,062 | 03-02-2023 |
$10.0101 | $0 | $10.0101 | $0 | $0 | 137 | 03-01-2023 |
$10.0101 | $0 | $10.0101 | $0 | $0 | 14 | 02-27-2023 |
$10.0101 | $0 | $10.0101 | $0 | $0 | 1 | 02-24-2023 |
$10.0101 | $10.01 | $10.0101 | $10.0101 | $10.01 | 897 | 02-23-2023 |
$9.92 | $0 | $9.92 | $0 | $0 | 122 | 02-22-2023 |
$9.92 | $10 | $9.92 | $10.06 | $9.92 | 6,255 | 02-21-2023 |
$10.0701 | $10.3 | $10.0701 | $10.3 | $10.07 | 1,923 | 02-20-2023 |
$10.0701 | $10.3 | $10.0701 | $10.3 | $10.07 | 1,923 | 02-17-2023 |
$10.53 | $0 | $10.53 | $0 | $0 | 20 | 02-16-2023 |
$10.53 | $10.53 | $10.53 | $10.53 | $10.53 | 145 | 02-13-2023 |
$10.55 | $10.5 | $10.55 | $10.55 | $10.5 | 1,787 | 02-07-2023 |
$10.55 | $10.53 | $10.55 | $10.55 | $10.53 | 1,724 | 02-06-2023 |
$10.25 | $10.83 | $10.25 | $10.84 | $10.25 | 1,402 | 02-03-2023 |
$10.42 | $0 | $10.42 | $0 | $0 | 24 | 02-02-2023 |
$10.42 | $12 | $10.42 | $12 | $10.42 | 577 | 02-01-2023 |
$10.2 | $0 | $10.2 | $0 | $0 | 900 | 01-31-2023 |
News, Short Squeeze, Breakout and More Instantly...
Good Works II Acquisition Corp. Company Name:
GWII Stock Symbol:
NASDAQ Market:
Good Works II Acquisition Corp. (Nasdaq: GWII) (“Good Works II”), a publicly traded special purpose acquisition company (“SPAC”), and Direct Biologics, LLC (“Direct Biologics”), a late-stage biotechnology company, today announced the signing of ...
Direct Biologics leverages a proprietary extracellular vesicle platform technology designed to harness the power of bone marrow-derived mesenchymal stem cells to develop cell-free therapeutics Product candidate, ExoFlo ™ , is in a Phase 3 clinical trial for treating...